ATE545634T1 - Aromatisches säureether-derivat aus ligustrazin, herstellungsverfahren, pharmazeutische zusammensetzung und anwendung - Google Patents

Aromatisches säureether-derivat aus ligustrazin, herstellungsverfahren, pharmazeutische zusammensetzung und anwendung

Info

Publication number
ATE545634T1
ATE545634T1 AT08843800T AT08843800T ATE545634T1 AT E545634 T1 ATE545634 T1 AT E545634T1 AT 08843800 T AT08843800 T AT 08843800T AT 08843800 T AT08843800 T AT 08843800T AT E545634 T1 ATE545634 T1 AT E545634T1
Authority
AT
Austria
Prior art keywords
pharmaceutical composition
application
ligustrazine
aromatic acid
ether derivative
Prior art date
Application number
AT08843800T
Other languages
English (en)
Inventor
Yonghai Zhao
Fengshi Ma
Yong He
Qiang Wu
Feng Li
Original Assignee
Li Jiaming
He Guangwei
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Li Jiaming, He Guangwei filed Critical Li Jiaming
Application granted granted Critical
Publication of ATE545634T1 publication Critical patent/ATE545634T1/de

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D241/00—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings
    • C07D241/02—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings not condensed with other rings
    • C07D241/10—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings not condensed with other rings having three double bonds between ring members or between ring members and non-ring members
    • C07D241/12—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings not condensed with other rings having three double bonds between ring members or between ring members and non-ring members with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Hematology (AREA)
  • Diabetes (AREA)
  • Urology & Nephrology (AREA)
  • Vascular Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Medicinal Preparation (AREA)
AT08843800T 2007-10-26 2008-10-27 Aromatisches säureether-derivat aus ligustrazin, herstellungsverfahren, pharmazeutische zusammensetzung und anwendung ATE545634T1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
CN2007101634771A CN101143851B (zh) 2007-10-26 2007-10-26 川芎嗪芳酸醚类衍生物、制备方法和药物组合物与应用
PCT/CN2008/072840 WO2009056070A1 (fr) 2007-10-26 2008-10-27 Dérivé éther de l'acide aromatique ligustrazine, son procédé de préparation, composition pharmaceutique et application

Publications (1)

Publication Number Publication Date
ATE545634T1 true ATE545634T1 (de) 2012-03-15

Family

ID=39206606

Family Applications (1)

Application Number Title Priority Date Filing Date
AT08843800T ATE545634T1 (de) 2007-10-26 2008-10-27 Aromatisches säureether-derivat aus ligustrazin, herstellungsverfahren, pharmazeutische zusammensetzung und anwendung

Country Status (7)

Country Link
US (1) US8350033B2 (de)
EP (1) EP2213666B1 (de)
JP (1) JP5265691B2 (de)
CN (1) CN101143851B (de)
AT (1) ATE545634T1 (de)
ES (1) ES2382979T3 (de)
WO (1) WO2009056070A1 (de)

Families Citing this family (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN101143851B (zh) * 2007-10-26 2010-07-21 李家明 川芎嗪芳酸醚类衍生物、制备方法和药物组合物与应用
CN101812025B (zh) * 2010-04-15 2011-12-07 李家明 吡嗪芳酸醚类化合物、制备方法和医药应用
CN101851209B (zh) * 2010-06-21 2012-09-19 合肥医工医药有限公司 咪唑乙基香草酸醚、其制备方法及其医药用途
CN102675401B (zh) * 2011-03-09 2014-08-13 雷海民 抗肿瘤药物lqc-y的制备及其应用
CN104151388B (zh) * 2011-03-09 2016-08-31 思路迪（北京）医药科技有限公司 抗肿瘤药物lqc-y的制备及其应用
CN102675228B (zh) * 2011-03-16 2014-08-13 雷海民 一种治疗缺血性脑损伤中风及其后遗症的药物与制备方法
CN103467383B (zh) * 2013-09-13 2015-07-15 上海海虹实业(集团)巢湖今辰药业有限公司 一种丹皮酚与奥扎格雷偶联物及其药物组合物、医药用途
CN104513207B (zh) * 2013-10-08 2017-06-20 昆药集团股份有限公司 一种苄醇醚类化合物及其制备方法、制剂与应用
CN104557740B (zh) * 2013-10-17 2018-01-02 雷海民 具有神经保护活性的川芎嗪取代苯甲酸类衍生物(lqc‑a)及其应用
CN103864768B (zh) * 2014-03-04 2016-04-06 广西师范大学 川芎嗪茋类衍生物及其制备方法与应用
CN105801496B (zh) * 2014-12-31 2018-03-13 广州喜鹊医药有限公司 三氟乙酰肼类化合物及其制备方法和在制药中的应用
CN105017165B (zh) * 2015-07-07 2018-04-03 广州喜鹊医药有限公司 一种新的吡嗪衍生物及其制备方法和医药应用
CN108456179B (zh) * 2017-02-20 2021-09-28 雷鹏程 具有神经保护作用的化合物tva-x及其制备方法和应用
CN107556251B (zh) * 2017-08-23 2018-06-22 广东昊邦医药健康有限责任公司 一种磷酸川芎嗪衍生化合物及其药物组合物
CN112028875B (zh) * 2019-06-04 2023-08-15 南昌弘益科技有限公司 一类pgi2蛋白激动剂、txa2蛋白抑制剂的酸酐类化合物
CN110749679B (zh) * 2019-11-08 2022-11-01 华熙生物科技股份有限公司 一种三甲基吡嗪残留的检测方法
CN111825664B (zh) * 2020-08-01 2023-01-17 泰州学院 一种川芎嗪衍生物、制备方法和医药用途
CN114805224B (zh) * 2022-04-01 2024-03-22 山东大学 一种川芎嗪查尔酮衍生物及其制备方法与应用
CN115201372B (zh) * 2022-07-14 2023-11-10 四川新绿色药业科技发展有限公司 一种同时检测川芎和水蛭的薄层色谱方法

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN1184209C (zh) 2002-12-20 2005-01-12 山东大学 川芎醇酯类衍生物及其制备方法和含有川芎醇酯类衍生物的药物组合物与应用
CN101012201B (zh) * 2007-02-05 2010-07-28 中国药科大学 川芎嗪衍生物、其制备方法及其医药用途
CN101143851B (zh) * 2007-10-26 2010-07-21 李家明 川芎嗪芳酸醚类衍生物、制备方法和药物组合物与应用

Also Published As

Publication number Publication date
EP2213666A1 (de) 2010-08-04
CN101143851A (zh) 2008-03-19
US8350033B2 (en) 2013-01-08
WO2009056070A1 (fr) 2009-05-07
JP2011500736A (ja) 2011-01-06
ES2382979T3 (es) 2012-06-15
EP2213666B1 (de) 2012-02-15
CN101143851B (zh) 2010-07-21
EP2213666A4 (de) 2010-11-17
JP5265691B2 (ja) 2013-08-14
US20100228029A1 (en) 2010-09-09

Similar Documents

Publication Publication Date Title
ATE545634T1 (de) Aromatisches säureether-derivat aus ligustrazin, herstellungsverfahren, pharmazeutische zusammensetzung und anwendung
CY1117481T1 (el) Φαρμακευτικη συνθεση που περιεχει παραγωγο κινολινης
EA200701176A1 (ru) Новые соединения нафталина, способ их получения и фармацевтические композиции, содержащие их
DK2227476T3 (da) Tricykliske triazoliske forbindelser
SMP201100019B (it) Composti organici
EA201100875A1 (ru) Новые пиразол-4-n-алкоксикарбоксамиды в качестве микробиоцидов
RS51341B (en) INTERMEDIATE COMPOUNDS FOR THE TRANS-5-CHLOR-2-METHYL-2,3A, 12B-TETRAHYDRO-1H-DIBENZE [2,3; 6,7] OXEPINO [4,5-C] Pyrrole
BRPI0911476A2 (pt) compostos ativadores de glicoquinase de piridazinona, composição farmaceutica, uso dos compostos, método para tratamento de uma enfermidade e/ou distúbio metabólico e processo para a preparação dos compostos
WO2008108378A3 (en) Bicyclic oxomorpholine derivative
ME00680B (me) Nova jedinjenja diozmetina, postupak za njihovo dobijanje i farmaceutske kompozicije koje ih sadrže
MX2010008051A (es) Nuevos derivados de fluoroglicosidos aromaticos, productos farmaceuticos que comprenden dichos compuestos y uso de los mismos.
CY1110034T1 (el) Παραγωγα 1,2,4,5-τετραϋδρο-3h-βενζαζεπινων, μεθοδος παρασκευης αυτων και οι φαρμακευτικες συνθεσεις που τα περιεχουν
MX2010008361A (es) Derivados de arilamida oxazepinopirimidona sustituidos.
RS53613B1 (en) COMPOUNDS, COMPOSITIONS, AND PROCEDURES FOR TREATMENT OF BETA-AMYLOID DISEASES AND SYNUCLEINOPATHY
MA32428B1 (fr) Composition fongicide et procede pour lutter contre des maladies de plantes
WO2007020261A3 (de) Ausgewählte cgrp-antagonisten, verfahren zu deren herstellung sowie deren verwendung als arzneimittel
CY1115623T1 (el) Μεθοδος για την συνθεση 7,8-διμεθοξυ-1,3-διϋδρο-2η-3-βενζαζεπιν-2-ονης και εφαρμογη αυτης στη συνθεση της ιβαμπραδινης καθως επισης αλατων προσθηκης αυτης με ενα φαρμακευτικως αποδεκτο οξυ
MA32192B1 (fr) Composés dérivés d'azétidines, leur préparation et leur application en thérapeutique
GEP20135959B (en) Aryl piperazine and their usage as alpha2c antagonists
EA017249B8 (ru) Арил- и гетероарилзамещенные тетрагидробензо-1,4-диазепины и их применение для блокирования обратного захвата норэпинефрина, допамина и серотонина
DE502005008351D1 (de) Chinolinderivat, dessen verwendung, herstellung und dieses enthaltendes arzneimittel
EA200801366A1 (ru) Производные 3,6-дигидро-2-оксо-6н-1,3,4-тиадиазина
SE0401969D0 (sv) Piperidine derivatives
ATE540675T1 (de) Verbindungen zur behandlung von stoffwechselstörungen
WO2009028676A1 (ja) カルボニル化合物の製造方法およびカルボニル化合物の製造に用いる酸化促進剤